Evidence map›Paper›PMID 40989157›Full record

ArticleOpen medicine (Warsaw, Poland)2025

Procalcitonin and C-reactive protein as biomarkers for diagnosing and assessing the severity of acute cholecystitis.

Qisheng Hou, Huayu Li, Cheng Liu, Yujia Sun, Bo Wang, Hui Xiong, Si Liu

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qisheng HouDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Huayu LiDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Cheng LiuDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Yujia SunDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Bo WangDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Hui XiongDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.
Si LiuDepartment of Emergency, Peking University First Hospital, Beijing, 100034, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute cholecystitis (AC) is a common condition in emergency departments (EDs), where timely diagnosis and severity assessment are critical for treatment decisions and outcome prediction. Methods: This study included 194 patients with AC to evaluate the diagnostic and severity-grading performance of procalcitonin (PCT) and C-reactive protein (CRP). Receiver operating characteristic (ROC) curve analysis was used to determine optimal cut-off values for discriminating between severity grades according to the Tokyo Guidelines. Results: Elevated levels of PCT and CRP were observed in 73.2 and 67% of cases, respectively. PCT demonstrated a sensitivity of 75.6% and specificity of 64.8% at a cut-off value of ≤ 0.595 ng/mL for distinguishing grade I from grades II to III. For differentiating grade III from grades I to II, PCT showed a sensitivity of 62.5% and specificity of 92.1% at a cut-off value of ≥5.095 ng/mL. Similarly, CRP had a sensitivity of 82.9% and specificity of 64.8% at a cut-off value of ≤78 mg/L for grade I versus grades II to III, and a sensitivity of 62.5% and specificity of 69.7% at a cut-off value of ≥82.5 mg/L for grade III versus grades I to II. Conclusion: Both PCT and CRP are valuable biomarkers for diagnosing AC and assessing its severity.

Indexed as

acute cholecystitisdiagnosisprocalcitoninseverity gradingTokyo guidelines

Identifiers

PMID40989157
PMCPMC12452066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.